Double Switching From Infliximab to Biosimilars in IBD Double Switching From Infliximab to Biosimilars in IBD

Does double switching from infliximab to the biosimilars CT-P13 and then to SB2 impair the effectiveness, immunogenicity or safety of anti-TNF therapy?Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news